Aspen Insurance Holdings Reports Results For the Quarter and Nine Months Ended September 30, 2011

HAMILTON, Bermuda, Oct 27, 2011 (BUSINESS WIRE) -- --Net income per diluted share of $0.23 for the quarter ended September 30, 2011 compared with $1.08 in the same quarter last year

--Operating income per diluted share of $0.70 for the quarter ended September 30, 2011 compared with $0.79 in the same quarter last year

--Diluted book value per share of $38.27, broadly in line with the third quarter of 2010 and up 2.2% from June 30, 2011

--Annualized net income return on equity of 2.8% for the third quarter of 2011

--Annualized operating return on equity of 8.4% for the third quarter of 2011

--Combined ratio of 96.7%, or 85.5% excluding catastrophe losses for the third quarter of 2011, compared with a combined ratio of 94.4% or 89.9% excluding catastrophe losses for the third quarter of 2010

--Gross written premium of $495.6 million for the third quarter of 2011, including $26.6 million of positive prior year premium adjustments mainly in the reinsurance segment, compared with $415.8 million for the third quarter of 2010

Cancer cover is the grey area of private health insurance

With the number of successful cancer drugs in the UK having risen dramatically over the last 30 years, people are increasingly turning to private medical cover in order to take advantage of excellent new treatments that are not available on the NHS.

But insurance experts have warned that cancer cover can be a ‘grey area’ of private medical cover. Some health insurance customers are unaware that they not eligible for advanced cancer treatment like re-constructive surgery or stem cell therapy.